Belinostat
Belinostat is a pharmaceutical drug with 43 clinical trials. Currently 9 active trials ongoing. Historical success rate of 79.3%.
Success Metrics
Based on 23 completed trials
Phase Distribution
Phase Distribution
26
Early Stage
15
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
69.7%
23 of 33 finished
30.3%
10 ended early
9
trials recruiting
43
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Clinical Trials (43)
Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial Carcinoma
A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity
Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment
Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma
Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia
Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in PTCL
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
MRSI to Predict Response to RT/TMZ ± Belinostat in GBM
Extension Study for Patients Who Had Not Met Criteria for Discontinuation in Previous Sponsored Belinostat Trials
Belinostat in Relapsed or Refractory Peripheral T-Cell Lymphoma
Evaluating Safety & Efficacy Belinostat Combo w Nivo Alone & w Ipi in Patients w Treated Metastatic/Advanced Carcinomas w ARID1A Lof Mutation
Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer
Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 43